Christophe Bourdon was the CEO of Orphazyme, a rare disease drug developer. Funding history, background and contact routes on StartupFundraising.com.
Christophe Bourdon was the CEO of Orphazyme, a rare disease drug developer. He led the company through efforts to gain approval for its experimental therapy arimoclomol, designed to treat Niemann-Pick disease type C (NPC), in both Europe and the United States. He resigned from Orphazyme to become CEO of LEO Pharma.
Full founder directory · Investor directory · Company funding database · Fundraising library